Accession Number:

AD1050103

Title:

Lymph Node Metastases Optical Molecular Diagnostic and Radiation Therapy

Descriptive Note:

Technical Report,01 Mar 2016,28 Feb 2017

Corporate Author:

DARTMOUTH COLL HANOVER NH HANOVER United States

Personal Author(s):

Report Date:

2017-03-01

Pagination or Media Count:

32.0

Abstract:

Breast cancer metastases detection, imaging and management is limited by a key technical problem fundamental to the nature of imaging, which is that micro metastases cannot be visualized at a relevant stage, largely because most imaging is based upon structures and not molecular functions. The one tool commonly used for metastases imaging is nuclear medicine. Positron emission tomography, PET, is used for whole body imaging, of metastases, or Gamma probe imaging is used for sentinel lymph node detection. PET is extremely successful in clinical staging based upon detection of involvement in lymph nodes and secondary organs, but there are no tools to effectively sense early metastases. Gamma imaging of sentinel nodes is not a disease diagnostic, but rather just used to find the node and remove it for pathological inspection. As a result, we are in a situation where surgical node dissection procedures are the standard for detection and removal of metastases, but axillary node dissection has high morbidity and is only needed in about 25 of cases that it is done it. Surgical dissection is the result of the fact that there is no molecular imaging tool today which can routinely sense the presence of cancer cells in lymph nodes or organs at the micrometastases stage. The needed probe sensitivity would be in the uM to nM range with sub mm spatial resolution throughout the body. This lack of high spatial resolution molecular imaging is a key factor inhibiting breast metastases research and treatment.

Subject Categories:

  • Medicine and Medical Research
  • Radiobiology
  • Genetic Engineering and Molecular Biology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE